Purpose: In the study, we aimed to estimate the prognostic significance of PCAT-1 in patients with prostate cancer (PCa).
Methods: The expression of PCAT-1 in paired PCa tissues and normal controls was examined via quantitative real-time polymerase chain reaction (qRT-PCR). The influence of PCAT-1 level on clinical features was assessed using Chi-square test. The survival curves were plotted to estimate the prognosis of patients. And the Cox analysis was carried out to find promising predictive factors for patients.
Results: The expression level of PCAT-1 in PCa tissues was significantly elevated compared with the adjacent normal control (P<0.0001). The increased expression of PCAT-1 was affected by high Gleason score (P=0.017), positive serum PSA (P=0.011) and advanced TNM stage (P=0.003). The Kaplan-Meier survival curves showed that the overall survival rate of patients with high PCAT-1 expression was significantly lower than those with low PCAT-1 expression (P<0.001). Both univariate analysis (P=0.000, HR=10.623, 95%CI=5.798-19.464) and multivariate Cox regression analysis (P=0.000, HR=10.996, 95%CI=5.896-20.507) revealed that PCAT-1 could act as a prognostic biomarker for PCa patients.
Conclusion: Taken together, overexpression of PCAT-1 is involved in PCa progression and could be a potential prognostic biomarker for PCa patients.